↓ Skip to main content

A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome

Overview of attention for article published in Schizophrenia Research, May 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (51st percentile)

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
11 Dimensions

Readers on

mendeley
80 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
A systematic review and meta-analysis of the effect of depot antipsychotic frequency on compliance and outcome
Published in
Schizophrenia Research, May 2015
DOI 10.1016/j.schres.2015.04.028
Pubmed ID
Authors

Steve Kisely, Emily Sawyer, Gail Robinson, Dan Siskind

Abstract

Depot antipsychotics are commonly used to improve adherence and clinical outcomes such as relapse and readmission. Dosing regimens vary but are commonly two- and four-weekly. To date, the effect of administration at two-weekly or four-weekly intervals on outcome has not been examined in a meta-analysis. A systematic review and meta-analysis on whether the frequency of depot antipsychotic administration (e.g., two- vs four-weekly) makes any difference to compliance and outcome. A systematic search of Medline, EMBASE and PsycInfo for RCTs that compared the frequency of depot administration (e.g., two- vs four-weekly) for an equivalent dose. Outcomes were compliance, psychiatric symptomatology, quality of life, adverse drug reactions (ADRs), patient preference, admission rates, bed-days and costs. Seven studies from eight papers (n=3994) were found covering olanzapine, paliperidone, risperidone, haloperidol and fluphenazine enanthate/decanoate with follow-up of up to one year. Meta-analyses were possible for psychotic symptoms and ADRs. There were no differences in psychotic symptoms or quality of life between two- and four-weekly doses. Health service use was not reported. For ADRs, the only significant difference detected was that two-weekly injections were less likely to lead to site pain (RR 0.16, 95% CI 0.07-0.38; 2 studies n=1667). There were no differences in other ADRs. There were surprisingly little data on the effect of dosing frequency for an equivalent dose on clinical outcomes. There is a need for long-term studies of a wide range of outcomes including cost-effectiveness. Claims for advantages of new preparations over others require careful evaluation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 80 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 1%
Cameroon 1 1%
Netherlands 1 1%
Unknown 77 96%

Demographic breakdown

Readers by professional status Count As %
Researcher 12 15%
Student > Master 11 14%
Student > Postgraduate 6 8%
Student > Bachelor 6 8%
Other 5 6%
Other 16 20%
Unknown 24 30%
Readers by discipline Count As %
Medicine and Dentistry 22 28%
Psychology 10 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 6%
Neuroscience 3 4%
Social Sciences 3 4%
Other 7 9%
Unknown 30 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 May 2016.
All research outputs
#16,047,334
of 25,373,627 outputs
Outputs from Schizophrenia Research
#3,276
of 5,686 outputs
Outputs of similar age
#148,956
of 279,401 outputs
Outputs of similar age from Schizophrenia Research
#47
of 120 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 34th percentile – i.e., 34% of other outputs scored the same or lower than it.
So far Altmetric has tracked 5,686 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.6. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 279,401 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 43rd percentile – i.e., 43% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 120 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 51% of its contemporaries.